Literature DB >> 15637150

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.

J S Ungerstedt1, Y Sowa, W-S Xu, Y Shao, M Dokmanovic, G Perez, L Ngo, A Holmgren, X Jiang, P A Marks.   

Abstract

This study examines the basis of resistance and sensitivity of normal and transformed cells to histone deacetylase inhibitor (HDACi)-induced cell death, specifically the role of caspases and thioredoxin (Trx). An important attribute of HDACis is that they induce cancer cell death at concentrations to which normal cells are relatively resistant, making them well suited for cancer therapy. The mechanism underlying this selectivity has not been understood. In this study we found that the HDACi suberoylanilide hydroxamic acid (SAHA) and MS-275, a benzamide, cause an accumulation of reactive oxygen species (ROS) and caspase activation in transformed but not normal cells. Inhibition of caspases does not block HDACi-induced cell death. These studies provide a possible mechanism that can explain why normal but not certain transformed cells are resistant to HDACi-induced cell death. The HDACi causes an increase in the level of Trx, a major reducing protein for many targets, in normal cells but not in transformed cells. The SAHA-induced increase in Trx activity in normal cells is associated with no increase in ROS accumulation. Transfection of transformed cells with Trx small interfering RNA caused a marked decrease in the level of Trx protein with an increase in ROS, a decrease in cell proliferation, and an increase in sensitivity to SAHA-induced cell death. Thus, Trx, independent of the caspase apoptotic pathway, is an important determinant of resistance of cells to HDACi-induced cell death.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15637150      PMCID: PMC543461          DOI: 10.1073/pnas.0408732102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  Functional significance of histone deacetylase diversity.

Authors:  S Khochbin; A Verdel; C Lemercier; D Seigneurin-Berny
Journal:  Curr Opin Genet Dev       Date:  2001-04       Impact factor: 5.578

Review 2.  Histone deacetylases, transcriptional control, and cancer.

Authors:  W D Cress; E Seto
Journal:  J Cell Physiol       Date:  2000-07       Impact factor: 6.384

3.  Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.

Authors:  X Liu; C N Kim; J Yang; R Jemmerson; X Wang
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

4.  Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.

Authors:  Yufang Shao; Zhonghua Gao; Paul A Marks; Xuejun Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-13       Impact factor: 11.205

5.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Authors:  V M Richon; T W Sandhoff; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

6.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.

Authors:  A A Ruefli; M J Ausserlechner; D Bernhard; V R Sutton; K M Tainton; R Kofler; M J Smyth; R W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

Review 7.  Physiological functions of thioredoxin and thioredoxin reductase.

Authors:  E S Arnér; A Holmgren
Journal:  Eur J Biochem       Date:  2000-10

8.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

9.  Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication.

Authors:  L Shao; M B Diccianni; T Tanaka; R Gribi; A L Yu; J D Pullen; B M Camitta; J Yu
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 10.  The role of the redox protein thioredoxin in cell growth and cancer.

Authors:  G Powis; D Mustacich; A Coon
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

View more
  172 in total

1.  LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

Authors:  Roberto Rosato; Stefanie Hock; Paul Dent; Yun Dai; Steven Grant
Journal:  Leuk Res       Date:  2011-11-08       Impact factor: 3.156

2.  Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock.

Authors:  Yongqing Li; Hasan B Alam
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Chidamide shows synergistic cytotoxicity with cytarabine via inducing G0/G1 arrest and apoptosis in myelodysplastic syndromes.

Authors:  Zhaoyun Liu; Jin Chen; Honglei Wang; Kai Ding; Yanqi Li; Anya de Silva; Varun Sehgal; Jonathan Lvan Burbano; Radhika Sundararaj; Janani Gamage; Victor Audu; Rong Fu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 4.  Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?

Authors:  Roderick H Dashwood; Melinda C Myzak; Emily Ho
Journal:  Carcinogenesis       Date:  2005-11-02       Impact factor: 4.944

5.  Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.

Authors:  Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

6.  Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

Authors:  Girija Dasmahapatra; Dmitry Lembersky; Minkyeong P Son; Elisa Attkisson; Paul Dent; Richard I Fisher; Jonathan W Friedberg; Steven Grant
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

Review 7.  Dietary agents as histone deacetylase inhibitors.

Authors:  Melinda C Myzak; Emily Ho; Roderick H Dashwood
Journal:  Mol Carcinog       Date:  2006-06       Impact factor: 4.784

8.  Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways.

Authors:  Jianbin Zhang; Shukie Ng; Jigang Wang; Jing Zhou; Shi-Hao Tan; Naidi Yang; Qingsong Lin; Dajing Xia; Han-Ming Shen
Journal:  Autophagy       Date:  2015-04-03       Impact factor: 16.016

9.  Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.

Authors:  Nadejda Beliakova-Bethell; Jin X Zhang; Akul Singhania; Vivian Lee; Valeri H Terry; Douglas D Richman; Celsa A Spina; Christopher H Woelk
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

10.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.